A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Livmoniplimab in Combination With Budigalimab in Chinese Subjects With Locally Advanced or Metastatic Child-Pugh A Hepatocellular Carcinoma Who Have Progressed After a First-Line Regimen That Includes an Immune Checkpoint Inhibitor
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Budigalimab (Primary) ; Livmoniplimab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 08 Jan 2025 Planned End Date changed from 27 Oct 2027 to 1 Oct 2027.
- 08 Jan 2025 Planned primary completion date changed from 27 Oct 2027 to 1 Oct 2027.
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.